Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking strategy to diabetes management. These innovative medications function by mimicking the natural actions of GLP-1, a hormone released by the gut in response to food. By triggering GLP-1 receptors in the pancreas, these substances boost insulin release and reduce glucagon r

The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight decrease – they exhibit intriguing contrasts in their